Dr. Clay Siegall is the founder and CEO of Seattle Genetics. The company has been around since 1998 and has provided cancer treatments to patients that were not responding well to other forms of treatment. Dr. Siegall had extensive experience with other pharmaceutical giants, which allowed him to realize his dream of helping people beat cancer. The foundation of Seattle Genetics is based on research and development combined with scientific innovation. His cancer research team created the first antibody-drug conjugate called Adcetris. Adcetris is currently their biggest generator or revenue and is now available in over sixty-five countries. Other treatments that are similar are in the final phases of testing and will be available to the public soon.
Dr. Clay Siegall has worked with companies such as GlaxoSmithKline, Pfizer, and Genentech to issues licensing to them for treatments. Dr. Siegall has also been able to raise an incredible $1.2 billion in funds through sources both public and private. This is a total that had begun when the company was available on the public market, which was in 2001.The total revenue from issuing licenses to other pharmaceutical companies has totaled over $350 million.
In addition to his incredible work with Seattle Genetics, Dr.Clay Siegall has previously worked with the National Cancer Institute, the National Institutes of Health, and Bristol-Myers Squibb Pharmaceutical Research Institute. He also serves on the Board of Directors for various institutions including Alder BioPharmaceuticals, Washington Roundtable, and Ultragenyx Pharmaceutical. He also received the award for Entrepreneur of the Year in 2012 from Pacific Northwest Ernst & Young, and Alumnus of the Year in 2013 from the University of Maryland for Computer, Math, and Natural Science. Dr. Clay Siegall attended the University of Maryland where he received his B.S. in Zoology and later received his Ph.D. in Genetics from George Washington University.